1) Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
2) Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955-8.
3) Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40:293-5.
4) Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti- VEGF agents. Br J Ophthalmol 2011;95:1111-4.
5) Mayhan WG. VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway. Am J Physiol 1999;276:C1148-53.
6) Breslin JW, Pappas PJ, Cerveira JJ, et al. VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. Am J Physiol Heart Circ Physiol 2003;284:H92-100.
7) Bouloumié A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999;41:773-80.
8) Dulak J, Józkowicz A, Dembinska-Kiec A, et al. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000;20:659-66.
9) Tilton RG, Chang KC, LeJeune WS, et al. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci 1999;40:689-96.
10) Lakshminarayanan S, Antonetti DA, Gardner TW, Tarbell JM. Effect of VEGF on retinal microvascular endothelial hydraulic conductivity: the role of NO. Invest Ophthalmol Vis Sci 2000;41:4256-61.
11) Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology 1984;91:564-79.
12) Rohen JW, LÜtjen-Drecoll E, FlÜgel C, et al. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp Eye Res 1993;56:683-92.
13) Keller KE, Aga M, Bradley JM, et al. Extracellular matrix turnover and outflow resistance. Exp Eye Res 2009;88:676-82.
15) Unemori EN, Ferrara N, Bauer EA, Amento EP. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992;153:557-62.
16) Lamoreaux WJ, Fitzgerald ME, Reiner A, et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998;55:29-42.
17) Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 1998;83:832-40.
18) Stamer WD, Clark AF. The many faces of the trabecular meshwork cell. Exp Eye Res 2017;158:112-23.
19) Grimes PA, Stone RA, Laties AM, Li W. Carboxyfluorescein. A probe of the blood-ocular barriers with lower membrane permeability than fluorescein. Arch Ophthalmol 1982;100:635-9.
20) Araie M. Carboxyfluorescein. A dye for evaluating the corneal endothelial barrier function in vivo. Exp Eye Res 1986;42:141-50.
24) Green LC, Wagner DA, Glogowski J, et al. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982;126:131-8.
25) Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma 2010;19:437-41.
26) Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007;245:1837-42.
27) Kim SH, Kim JW. Effect of bevacizumab on survival and production of nitric oxide in trabecular meshwork cells. J Korean Ophthalmol Sci 2009;50:1404-8.
29) Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci 1998;39:2649-58.
30) Pang IH, Hellberg PE, Fleenor DL, et al. Expression of matrix metalloproteinases and their inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2003;44:3485-93.
31) Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274:H1054-8.
32) Wiederholt M, Sturm A, Lepple-Wienhues A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Invest Ophthalmol Vis Sci 1994;35:2515-20.
33) Behar-Cohen FF, Goureau O, D’Hermies F, Courtois Y. Decreased intraocular pressure induced by nitric oxide donors is correlated to nitrite production in the rabbit eye. Invest Ophthalmol Vis Sci 1996;37:1711-5.
34) Nathanson JA, McKee M. Alterations of ocular nitric oxide synthase in human glaucoma. Invest Ophthalmol Vis Sci 1995;36:1774-84.
35) Löffek S, Schilling O, Franzke CW. Series "matrix metalloproteinases in lung health and disease": biological role of matrix metalloproteinases: a critical balance. Eur Respir J 2011;38:191-208.
36) Yoshida M, Sagawa N, Itoh H, et al. Nitric oxide increases matrix metalloproteinase-1 production in human uterine cervical fibroblast cells. Mol Hum Reprod 2001;7:979-85.
37) Chen HH, Wang DL. Nitric oxide inhibits matrix metalloproteinase-2 expression via the induction of activating transcription factor 3 in endothelial cells. Mol Pharmacol 2004;65:1130-40.
38) Gurjar MV, Sharma RV, Bhalla RC. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol 1999;19:2871-7.
39) Alexander JP, Samples JR, Van Buskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci 1991;32:172-80.
40) Komarova Y, Malik AB. Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu Rev Physiol 2010;72:463-93.
41) Ethier CR. The inner wall of Schlemm's canal. Exp Eye Res 2002;74:161-72.
42) Tripathi RC. Mechanism of the aqueous outflow across the trabecular wall of Schlemm's canal. Exp Eye Res 1971;11:116-21.
43) Tarkkanen A, Niemi M. Enzyme histochemistry of the angle of the anterior chamber of the human eye. Acta Ophthalmol (Copenh) 1967;45:93-9.
44) Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 2006;58:15-28.
45) Feng Y, Venema VJ, Venema RC, et al. VEGF-induced permeability increase is mediated by caveolae. Invest Ophthalmol Vis Sci 1999;40:157-67.